Can the Retinal Screening Interval Be Safely Increased to 2 Years for Type 2 Diabetic Patients Without Retinopathy?
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In the U.K., people with diabetes are typically screened for retinopathy annually. However, diabetic retinopathy sometimes has a slow progression rate. We developed a simulation model to predict the likely impact of screening patients with type 2 diabetes, who have not been diagnosed with diabetic retinopathy, every 2 years rather than annually. We aimed to assess whether or not such a policy would increase the proportion of patients who developed retinopathy-mediated vision loss compared with the current policy, along with the potential cost savings that could be achieved. RESEARCH DESIGN AND METHODS: We developed a model that simulates the progression of retinopathy in type 2 diabetic patients, and the screening of these patients, to predict rates of retinopathy-mediated vision loss. We populated the model with data obtained from a National Health Service Foundation Trust. We generated comparative 15-year forecasts to assess the differences between the current and proposed screening policies. RESULTS: The simulation model predicts that implementing a 2-year screening interval for type 2 diabetic patients without evidence of diabetic retinopathy does not increase their risk of vision loss. Furthermore, we predict that this policy could reduce screening costs by ∼25%. CONCLUSIONS: Screening people with type 2 diabetes, who have not yet developed retinopathy, every 2 years, rather than annually, is a safe and cost-effective strategy. Our findings support those of other studies, and we therefore recommend a review of the current National Institute for Health and Clinical Excellence (NICE) guidelines for diabetic retinopathy screening implemented in the U.K.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Artificial intelligence approaches to screening for diabetic retinopathy have progressed to the point of utility and cost-effectiveness.508–513”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [510]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
The Wisconsin Epidemiologic Study of Diabetic Retinopathy
Klein, R., Klein, B. E. K., Moss, S. E., Davis, M. D., & DeMets, D. L. (1987) · Ophthalmology · doi:10.1016/s0161-6420(87)33525-0 · Cited by 1,249
Fong, D. S., Aiello, L., Gardner, T. W., King, G. L., Blankenship, G., Cavallerano, J. D., Ferris, F. L., Klein, R., & for the American Diabetes Association (2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s84 · Cited by 1,082
Stratton, I. M., Kohner, E. M., Aldington, S. J., Turner, R. C., Holman, R. R., Manley, S. E., & Matthews, D. R. (2001) · Diabetologia · doi:10.1007/s001250051594 · Cited by 1,019
Kohner, E. M. (1998) · Archives of Ophthalmology · doi:10.1001/archopht.116.3.297 · Cited by 474
Klein, R. (1989) · Archives of Ophthalmology · doi:10.1001/archopht.1989.01070010243030 · Cited by 470
Davis, M. D., Fisher, M. R., Gangnon, R. E., Barton, F. B., Aiello, L. M., Chew, E. Y., Ferris, F. L., & Knatterud, G. L. (1998) · PubMed · Cited by 455
Klein, R. (1989) · Archives of Ophthalmology · doi:10.1001/archopht.1989.01070010250031 · Cited by 361 · cited 2×
“We conducted an extensive search of papers published after the Wisconsin Epidemiologic Study of Diabetic Retinopathy (12), upon which the POST study was based (1,11), to see if there had been any newer, but similar, large-scale cohort studies that drew from a wide diabetic population and looked at the progression of d…”
MethodResultTrends in the prevalence and incidence of diabetes in the UK: 1996–2005
González, E. L. M., Johansson, S., Wallander, M.-A., & Rodríguez, L. A. G. (2009) · Journal of Epidemiology and Community Health · doi:10.1136/jech.2008.080382 · Cited by 297 · cited 1×
“42/ 1,000 person-years in the model as an initial estimate (17) and increased this by 4.”
BackgroundYounis, N., Broadbent, D. M., Vora, J. P., & Harding, S. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12267-2 · Cited by 289
Cited by
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
van der Heijden, A. A., Abramoff, M. D., Verbraak, F., van Hecke, M. V., Liem, A., & Nijpels, G. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13613 · Cited by 296
“Screening for DR has proven to be effective in the prevention of blindness, and some national health authorities and most professional organizations have adopted an annual or biennial screening programme which is usually integrated within regular diabetes care (Olafsdottir & Stefansson 2007; Rodbard et al. 2007; Scanl…”
BackgroundLearning ensemble classifiers for diabetic retinopathy assessment
Saleh, E., Błaszczyński, J., Moreno, A., Valls, A., Romero-Aroca, P., de la Riva-Fernández, S., & Słowiński, R. (2018) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2017.09.006 · Cited by 97
Corcóstegui, B., Durán, S., González-Albarrán, M. O., Hernández, C., Ruiz‐Moreno, J. M., Salvador, J., Udaondo, P., & Simó, R. (2017) · Journal of Ophthalmology · doi:10.1155/2017/8234186 · Cited by 90
“Other studies have also shown that the strategy of biannual screening is safe and cost-effective for subjects who have not developed DR [29, 30].”
BackgroundExtending the diabetic retinopathy screening interval beyond 1 year: systematic review
Taylor-Phillips, S., Mistry, H., Leslie, R., Todkill, D., Tsertsvadze, A., Connock, M., & Clarke, A. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305938 · Cited by 83
on behalf of the Scottish Diabetes Research Network (SDRN) Epidemiology Group and the Scottish Diabetic Retinopathy Collaborative, Looker, H. C., Nyangoma, S. O., Cromie, D. T., Olson, J. A., Leese, G. P., Philip, S., Black, M. W., Doig, J., Lee, N., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-2928-7 · Cited by 80
Shah, A., Clarida, W., Amelon, R., Hernaez-Ortega, M. C., Navea, A., Morales-Olivas, J., Dolz-Marco, R., Verbraak, F., Jorda, P. P., van der Heijden, A. A., et al. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820906212 · Cited by 68
Telemedicine for screening diabetic retinopathy: The NO BLIND Italian multicenter study
Sasso, F. C., Pafundi, P. C., Gelso, A., Bono, V., Costagliola, C., Marfella, R., Sardu, C., Rinaldi, L., Galiero, R., Acierno, C., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3113 · Cited by 62
Screening Intervals for Diabetic Retinopathy and Implications for Care
Scanlon, P. H. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0928-6 · Cited by 59
Bardisi, W. M., Magliah, S. F., Attah, M. A., & Khorsheed, M. M. (2018) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_85_18 · Cited by 70
A decade-long telemedicine screening program for diabetic retinopathy in the north-east of Italy
Vujosevic, S., Pucci, P., Casciano, M., Daniele, A., Bini, S., Berton, M., Cavarzeran, F., Avogaro, A., Lapolla, A., & Midena, E. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.04.010 · Cited by 46
Validation of a model to estimate personalised screening frequency to monitor diabetic retinopathy
van der Heijden, A. A. W. A., Walraven, I., Riet, E. V. ‘., Aspelund, T., Lund, S. H., Elders, P. J. M., Polak, B. C. P., Moll, A. C., KEUNEN, J. E. E., Dekker, J. M., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3246-4 · Cited by 44
Scanlon, P. H., STRATTON, I. M., Histed, M. H., Chave, S., & Aldington, S. J. (2013) · Acta Ophthalmologica · doi:10.1111/aos.12074 · Cited by 44
“This risk may be based on a previous screening result (Agardh & Tababat-Khani 2011; Chalk et al. 2012; Olafsdottir & Stefansson 2007; Younis et al. 2003a,b) or on the basis of previously defined individual risk factors (Mehlsen et al. 2011, 2012).”
Backgroundfor the Individualised Screening for Diabetic Retinopathy (ISDR) Study Group, Eleuteri, A., Fisher, A. C., Broadbent, D. M., García-Fiñana, M., Cheyne, C. P., Wang, A., Stratton, I. M., Gabbay, M., Seddon, D., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4386-0 · Cited by 39
Soto‐Pedre, E., Piniés, J. A., & Hernáez-Ortega, M. C. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.12.020 · Cited by 28
Clinical characteristics influence screening intervals for diabetic retinopathy
Porta, M., Maurino, M., Severini, S., Lamarmora, E., Trento, M., Sitia, E., Coppo, E., Raviolo, A., Carbonari, S., Montanaro, M., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-2989-7 · Cited by 26
Serum cystatin C for risk stratification of prediabetes and diabetes populations
Xiong, K., Zhang, S., Zhong, P., Zhu, Z., Chen, Y., Huang, W., & Wang, W. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102882 · Cited by 25
Yang, C. G., Liu, Q., Guo, H., Zhang, M., Zhang, L., Zhang, G., Zeng, J., Huang, Z., Meng, Q., & Cui, Y. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.773881 · Cited by 22
“The National Health Service Foundation Trust claimed that screening people with type 2 diabetes every 2 years, rather than annually, would reduce screening costs by 25% (7).”
BackgroundDay, T. E., Ravi, N., Xian, H., & Brugh, A. (2014) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2014.01.007 · Cited by 16
“There is growing evidence from both real-world [5,6] and simulated [7] studies that it is safe to screen diabetic patients who do not yet exhibit DR biannually instead of annually.”
BackgroundResultInfluentialThomas, R., Winfield, T. G., Prettyjohns, M., Dunstan, F., Cheung, W., Anderson, P. M., Peter, R., Luzio, S. D., & Owens, D. R. (2020) · The European Journal of Health Economics · doi:10.1007/s10198-020-01191-y · Cited by 18
“Previous studies that have assessed the cost effectiveness of extending screening intervals have either focussed solely on people with T2DM [22, 23] or have combined people with T1DM and T2DM into one group [10, 25] and found that increasing screening intervals to 2-5 years to be safe and cost effective in those at lo…”
BackgroundModelling self-management pathways for people with diabetes in primary care
Penn, M., Kennedy, A. P., Vassilev, I., Chew-Graham, C. A., Protheroe, J., Rogers, A. E., & Monks, T. (2015) · BMC Family Practice · doi:10.1186/s12875-015-0325-7 · Cited by 14
A personalised screening strategy for diabetic retinopathy: a cost-effectiveness perspective
Emamipour, S., van der Heijden, A. A. W. A., Nijpels, G., Elders, P. J. M., Beulens, J. W. J., Postma, M. J., van Boven, J. F. M., & Feenstra, T. (2020) · Diabetologia · doi:10.1007/s00125-020-05239-9 · Cited by 18
Guidelines on glaucoma and the demand for services
Chalk, D., & Smith, M. R. (2013) · British Journal of Healthcare Management · doi:10.12968/bjhc.2013.19.10.476 · Cited by 14
Self-citationClarke, K. M., Webster, L., Althauser, S., Anderson, J., STRATTON, I. M., Brackenridge, A., & Mann, S. S. (2023) · Eye · doi:10.1038/s41433-023-02655-0 · Cited by 10
“Importantly, while the high maculopathy rate in this study could be explained by the increased proportion of women with type 2 diabetes in our cohort [14], improved detection methods, such as OCT scanning, are also likely to have played a role.”
BackgroundValidation of a Diagnostic Support System for Diabetic Retinopathy Based on Clinical Parameters
Romero‐Aroca, P., Verges, R., Santos-Blanco, E., Maaroof, N., Valls, A., Mundet, X., Moreno, A., Galindo, L., & Baget‐Bernaldiz, M. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.3.17 · Cited by 11
Assessment of Macular Function Using the SKILL Card in Adults With Type 2 Diabetes Mellitus
Dhamdhere, K. P., Schneck, M. E., Bearse, M. A., Lam, W., Barez, S., & Adams, A. J. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-13368 · Cited by 11
Diabetic Retinopathy Risk Estimation Using Fuzzy Rules on Electronic Health Record Data
Saleh, E., Valls, A., Moreno, A., Romero‐Aroca, P., de la Riva-Fernández, S., & Sagarra-Alamo, R. (2016) · Lecture notes in computer science · doi:10.1007/978-3-319-45656-0_22 · Cited by 6
Saleh, E., Moreno, A., Valls, A., Romero‐Aroca, P., & Sofia, D. L. R.-F. (2016) · Frontiers in artificial intelligence and applications · doi:10.3233/978-1-61499-696-5-169 · Cited by 8
Peris‐Martínez, C., Shaha, A., Clarida, W., Amelon, R. E., Hernáez-Ortega, M. C., Návea, A., Morales-Olivas, J., Dolz‐Marco, R., Pérez-Jordá, P., Verbraak, F. D., et al. (2020) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2020.08.007 · Cited by 8
James, M., Goodchild, C., Bashir, S., & Mannix, M. (2015) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-015-1248-y · Cited by 5
Harding, S. P., Alshukri, A., Appelbe, D., Broadbent, D., Burgess, P. I., Byrne, P., Cheyne, C. P., Eleuteri, A., Fisher, A., García‐Fiñana, M., et al. (2023) · Programme Grants for Applied Research · doi:10.3310/hrfa3155 · Cited by 6
Screening for sight-threatening diabetic retinopathy: An update
Scanlon, P. H., Dirani, M., & van Wijngaarden, P. (2014) · Egyptian Retina Journal · doi:10.4103/2347-5617.152479 · Cited by 4
“Based on a previous screening result[58-60] b.”
Peris‐Martínez, C., Shaha, A., Clarida, W., Amelon, R. E., Hernáez-Ortega, M. C., Návea, A., Morales-Olivas, J., Dolz‐Marco, R., Pérez-Jordá, P., Verbraak, F. D., et al. (2020) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2020.08.002 · Cited by 4
Aravindhan, A., Fenwick, E., Chan, A. W. D., Man, R. E. K., Tan, N. C., Wong, W. T., Soo, W. F., Lim, S. W., Wee, S. Y.-M., Sabanayagam, C., et al. (2024) · BMC Public Health · doi:10.1186/s12889-024-18287-2 · Cited by 4
“The sample size to develop a DR/DME risk stratification model was based on estimates of progression rates and probabilities of referable DR/DME from the literature [37].”
MethodReal-world outcomes of a clinical decision support system for diabetic retinopathy in Spain
Romero‐Aroca, P., Verges, R., Maaroof, N., Mateu, A. V., Latorre, A., Moreno, A., Sagarra-Alamo, R., Basora, J., Cristiano, J., & Baget‐Bernaldiz, M. (2022) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2022-000974 · Cited by 5
Pereira, A. P., Macêdo, J., Afonso, A., Laureano, R. M. D. S., & Neto, F. B. D. L. (2024) · Scientific Reports · doi:10.1038/s41598-024-55517-4 · Cited by 4
Romero‐Aroca, P., Baget‐Bernaldiz, M., Navarro-Gil, R., Feliu, A., Maarof, N., Moreno, A., Cristiano, J., & Valls, A. (2022) · Clinical ophthalmology · doi:10.2147/opth.s351790 · Cited by 2
MODELING DISEASES: PREVENTION, CURE AND MANAGEMENT
Currie, C. S. M., & Monks, T. (2018) · Winter Simulation Conference · doi:10.1109/wsc.2018.8632502 · Cited by 2
“2017), diabetes (Chalk et al. 2012; Davies et al. 2000) and heart disease models (Vasilakis et al.”
Pitt, M., Olvera‐Barrios, A., Anderson, J., Bolter, L., Chambers, R., Warwick, A., Mann, S. S., Webster, L., Fajtl, J., Barman, S. A., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06379-6 · Cited by 1
“While some previous research has suggested that it would be safe and effective to extend the time period between screening appointments for these ‘low-risk’ people [11–14], this research has mainly included people of white ethnicity.”
Self-citationA quantitative analysis of diabetic retinopathy screening in a regional treatment centre.
James, M., Th, H., & Minasyan, D. (2014) · PubMed · Cited by 1
Evaluating Diabetic Retinopathy Screening Interventions in a Microsimulation Model
Swan, B. P., Nambiar, S., Koutouan, P. R., Mayorga, M. E., Ivy, J. S., Fitts, E. P., & FRANSEN, S. R. (2020) · Winter Simulation Conference · doi:10.1109/wsc48552.2020.9384074 · Cited by 3
“Work by Chalk et al. (2012) showed the necessity of modeling both underlying disease states and delivery of care for DR. Nambiar et al. (2018) and Lich et al. (2019) used a microsimulation model for populationlevel colorectal cancer screening and interventions.”
BackgroundThe Relationship between Individual Risk and Cost-Effectiveness in Screening InterventionsPreprint
Sampson, C., James, M., & Whynes, D. K. (2013) · SSRN Electronic Journal · doi:10.2139/ssrn.2362371
“Similarly, Chalk et al find that extending the screening interval for low-risk individuals is a cost-effective strategy[11].”
The relationship between individual risk and cost-effectiveness in screening interventionsPreprint
Sampson, C., James, M., & Whynes, D. K. (2014) · RePEc: Research Papers in Economics · doi:10.6084/m9.figshare.1101308
Brown, R. (2021) · Enlighten: Theses (The University of Glasgow) · doi:10.5525/gla.thesis.82173 · Cited by 1
Evaluation of Macular Function Tests with Diabetic Retinopathy
Agrawal, A. A., & Shetty, N. (2021) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2021/307
Aravindhan, A., Fenwick, E., Chan, A. W. D., Man, R. E. K., Tan, N. C., Wong, W. T., Soo, W. F., Lim, S. W., Wee, S. Y.-M., Sabanayagam, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25405956
Aravindhan, A., Fenwick, E., Chan, A. W. D., Man, R. E. K., Tan, N. C., Wong, W. T., Soo, W. F., Lim, S. W., Wee, S. Y.-M., Sabanayagam, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25406100
Metadata
- Authors
- Chalk, D., Pitt, M., Vaidya, B., & Stein, K.
- Affiliations
- University of Exeter (GB)
- Royal Devon & Exeter NHS Foundation Trust (GB)
- Corresponding author
- Chalk, Daniel
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-07-14
- Volume
- 35
- Issue
- 8
- Pages
- 1663-1668
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3402259
- OpenAlex
- W2121408450
- Cited by
- 48
- References
- 28
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 6 · 2018: 3 · 2017: 6 · 2016: 2 · 2015: 6 · 2014: 5 · 2013: 5
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by-nc-nd)
- Open Research Exeter (University of Exeter) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic retinopathy screening, type 2 diabetes, screening frequency, retinopathy progression, vision loss, cost-effectiveness, computer simulation, NICE guidelines, National Health Service
- MeSH terms
- Diabetes Mellitus, Type 2, Diabetic Retinopathy, Female, Humans, Male, Mass Screening, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.